Portland, OR -- (SBWIRE) -- 09/18/2017 -- Norfloxacin is a synthetic broad spectrum antibiotic, which acts against most gram-negative and gram-positive bacteria. This antibiotic is mainly used to treat urinary tract infections by inhibiting bacterial cell division.

Access to the full summary: https://www.alliedmarketresearch.com/norfloxacin-market

The major factors that contribute to the growth of the norfloxacin market include the high prevalence of urinary tract infections (UTI), chronic diseases, and rise in geriatric population contributing to a large patient pool. Moreover, large number of clinical trials and innovative R&D approaches to develop advanced antibiotics drive the market growth. However, development of drug-resistant strains and side effects associated with the use of antibiotic restrain the market growth. The development of prospect molecules and novel combination therapies by R&D processes, which are used to treat antibiotic-resistant microbial infections further provides various opportunities for market growth.

The key players operating in this market include Janssen Pharmaceuticals, Merck KGaA, Eli. Lilly & Co., Bristol-Myers Squibb Company, GlaxoSmithKline plc, AbZ-Pharma GmbH, F. Hoffmann-La Roche AG, Shandong Xinhua Pharmaceutical, Kyorin Pharmaceutical Co., Ltd., and Lancer Health Care Pvt. Ltd.

Norfloxacin Market Key Segments:

By Brand Names

- Chibroxin
- Noroxin
- Others

By Application

- Uncomplicated Urinary Tract Infections
- Complicated Urinary Tract Infections
- Uncomplicated Urethral and Cervical Gonorrhea
- Prostatitis
- Others

Get sample PDF: https://www.alliedmarketresearch.com/request-toc-and-sample/4050

By Region

North America

- U.S.
- Canada
- Mexico

Europe

- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe

Asia-Pacific

- Japan
- China
- India
- Australia
- Rest of Asia-Pacific

LAMEA

- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA